Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.
-
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.
-
Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Feb; 270:172-182.
-
Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, Ho AC, Spirn MJ, Klufas MA, Garg SJ, Vander JF, Regillo CD, Chiang A, Kuriyan AE, Yonekawa Y. Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol. 2024 08 22; 108(9):1257-1262.
-
Lin TY, Hsieh YT, Garg SJ, Chen LJ, Chen KJ, Wu WC, Lai CC, Hwang YS, Kang EY. Systemic effects of anti-VEGF intravitreal injection in patients with age-related macular degeneration: A multi-institutional real-world study. Indian J Ophthalmol. 2024 11 01; 72(Suppl 5):S809-S815.
-
Dang S, Parke DW, Sodhi GS, Eichenbaum D, Nielsen J, Danzig C, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord K, Sheth V, Pieramici D, Orlin A, Madson A, Horton M, Blim J, Cao JA, Thompson J, Khanna S, Wykoff CC, Shah AR. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 08 01; 142(8):716-721.
-
Nanji K, Kennedy K, Fung M, Xie J, Hatamnejad A, Garg SJ, Wykoff CC, Chaudhary V. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 02; 60(1):e92-e99.
-
Cai CX, Nishimura A, Bowring MG, Westlund E, Tran D, Ng JH, Nagy P, Cook M, McLeggon JA, DuVall SL, Matheny ME, Golozar A, Ostropolets A, Minty E, Desai P, Bu F, Toy B, Hribar M, Falconer T, Zhang L, Lawrence-Archer L, Boland MV, Goetz K, Hall N, Shoaibi A, Reps J, Sena AG, Blacketer C, Swerdel J, Jhaveri KD, Lee E, Gilbert Z, Zeger SL, Crews DC, Suchard MA, Hripcsak G, Ryan PB. Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study. Ophthalmol Retina. 2024 08; 8(8):733-743.
-
Lee AY, Kovacs K, Orlin A, Kiss S, D'Amico DJ, Segal KL, Lelli GJ, Godfrey KJ. Incidence of Blepharoptosis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2024 Sep; 265:236-240.
-
Mandava NK, Kuriyan AE, Ho AC, Hsu J, Regillo CD, Klufas MA. Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema. Curr Opin Ophthalmol. 2024 May 01; 35(3):197-204.